Maruhashi K, Wada H, Taniguchi M, Koizumi S
Department of Pediatrics, Kanazawa University School of Medicine, Japan.
Rinsho Ketsueki. 1996 May;37(5):443-7.
A case of acute promyelocytic leukemia (APL) complicated by sinus bradyarrhythmia during the course of all-trans retinoic acid (ATRA) administration is reported. A 3-year-old boy was admitted for evaluation of petechiae and APL was diagnosed. He was initially treated with 45 mg/m2 of ATRA without success, and a complete remission was achieved when the dose was increased to 135 mg/m2. Sinus bradyarrhythmia was first recognized 3 days after the induction therapy with ATRA. It did not disappear even when the patient stopped taking the medication. However, the arrhythmia tended to be augmented whenever he received ATRA again. Close observation of his cardiac condition was mandatory to continue ATRA as an integral part of the therapy for APL, combined with multidrug chemotherapy including anthracyclines, which themselves are potentially toxic to myocardium. In conclusion, the present case revealed the possibility that ATRA therapy induces sinus node arrhythmia, or that it can potentiate preexisting node dysfunctions.
报告了1例急性早幼粒细胞白血病(APL)患者在全反式维甲酸(ATRA)治疗过程中并发窦性心动过缓的病例。一名3岁男孩因瘀点入院检查,被诊断为APL。他最初接受45mg/m²的ATRA治疗但未成功,当剂量增加到135mg/m²时实现了完全缓解。窦性心动过缓在ATRA诱导治疗3天后首次被发现。即使患者停药,该症状仍未消失。然而,每当他再次接受ATRA治疗时,心律失常往往会加重。由于ATRA是APL治疗不可或缺的一部分,且需联合包括蒽环类药物在内的多药化疗,而蒽环类药物本身对心肌有潜在毒性,因此必须密切观察他的心脏状况。总之,本病例揭示了ATRA治疗可能诱发窦性心律失常,或加重已有的窦房结功能障碍。